GERN Geron Corporation
Geron Corporation (GERN) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.3% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Geron Corporation
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies.
Sector
Healthcare
Industry
Drug Manufacturers/Other